Provectus Biopharmaceuticals Inc. And Sinopharm Facing MOU Deadline For Partnership

Provectus, a Tennessee clinical-stage biopharma, reiterated that the company remains committed to finding a China partner for its lead molecule, PV-10, a cancer treatment. In August 2014, Provectus signed a MOU with Sinopharm, a state-owned company, for China rights to PV-10. That agreement has been extended past its original 3-month limit, but it expires again next week, on May 16. Provectus said it hopes to sign a deal with Sinopharm prior to the date.

Help employers find you! Check out all the jobs and post your resume.

Back to news